Society of Infectious Diseases Pharmacists | Strategic Alliance Partners

Antimicrobial resistance continues to pose a significant health threat, necessitating new antibiotics with novel mechanisms to treat these complicated infections. However, between 2010 and 2018, newly approved antibiotics were primarily derived from previously established drug classes. This past summer, the FDA approved 2 new antibiotics.

Eravacycline, Omadacycline, Plazomicin, and a Rifamycin Add to the Armamentarium for Treating Resistant Infections

Pharmacy Times has announced the addition of the Society of Infectious Diseases Pharmacists (SIDP) to its Strategic Alliance Partnership (SAP) program.

Expansion to adolescents, flexible dosing strategies, innovative delivery models, and long-acting antiretrovirals all help the strategy.

Pharmacists who have patients receiving the antibiotic should familiarize themselves with the methods for optimizing this agent.

The newly FDA-approved drug blocks viral replication and RNA transcription via a cap-dependent endonuclease inhibitor.